Works matching AU Yamamoto, Shutaro


Results: 22
    1

    Predicting Objective Response of Pembrolizumab in Platinum-Refractory Urothelial Carcinoma Based on Neutrophil-Lymphocyte Ratio Fluctuation and Liver Metastases.

    Published in:
    Oncology, 2024, v. 102, n. 6, p. 457, doi. 10.1159/000534554
    By:
    • Nishio, Kyosuke;
    • Higashio, Takuya;
    • Komura, Kazumasa;
    • Fukuokaya, Wataru;
    • Adachi, Takahiro;
    • Hirasawa, Yosuke;
    • Hashimoto, Takeshi;
    • Yoshizawa, Atsuhiko;
    • Tsuchida, Shuya;
    • Matsuda, Takuya;
    • Tsujino, Takuya;
    • Nishimura, Kazuki;
    • Tokushige, Satoshi;
    • Nakamori, Keita;
    • Uchimoto, Taizo;
    • Yamamoto, Shutaro;
    • Iwatani, Kosuke;
    • Urabe, Fumihiko;
    • Mori, Keiichiro;
    • Yanagisawa, Takafumi
    Publication type:
    Article
    2

    Fetal-to-fetal kidney transplantation in utero.

    Published in:
    Communications Biology, 2025, v. 8, n. 1, p. 1, doi. 10.1038/s42003-025-07783-9
    By:
    • Morimoto, Keita;
    • Yamanaka, Shuichiro;
    • Matsui, Kenji;
    • Kinoshita, Yoshitaka;
    • Inage, Yuka;
    • Yamamoto, Shutaro;
    • Koda, Nagisa;
    • Matsumoto, Naoto;
    • Saito, Yatsumu;
    • Takamura, Tsuyoshi;
    • Fujimoto, Toshinari;
    • Fukunaga, Shohei;
    • Tajiri, Susumu;
    • Matsumoto, Kei;
    • Ozawa, Katsusuke;
    • Wada, Seiji;
    • Kobayashi, Eiji;
    • Yokoo, Takashi
    Publication type:
    Article
    3
    4

    Caspase 9-induced apoptosis enables efficient fetal cell ablation and disease modeling.

    Published in:
    Nature Communications, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41467-025-57795-6
    By:
    • Matsui, Kenji;
    • Watanabe, Masahito;
    • Yamamoto, Shutaro;
    • Kawagoe, Shiho;
    • Ikeda, Takumi;
    • Ohashi, Hinari;
    • Kuroda, Takafumi;
    • Koda, Nagisa;
    • Morimoto, Keita;
    • Kinoshita, Yoshitaka;
    • Inage, Yuka;
    • Saito, Yatsumu;
    • Fukunaga, Shohei;
    • Fujimoto, Toshinari;
    • Tajiri, Susumu;
    • Matsumoto, Kei;
    • Kobayashi, Eiji;
    • Yokoo, Takashi;
    • Yamanaka, Shuichiro
    Publication type:
    Article
    5
    6
    7
    8

    C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.

    Published in:
    Targeted Oncology, 2024, v. 19, n. 4, p. 635, doi. 10.1007/s11523-024-01068-7
    By:
    • Uchimoto, Taizo;
    • Matsuda, Takuya;
    • Komura, Kazumasa;
    • Fukuokaya, Wataru;
    • Adachi, Takahiro;
    • Hirasawa, Yosuke;
    • Hashimoto, Takeshi;
    • Yoshizawa, Atsuhiko;
    • Saruta, Masanobu;
    • Hashimoto, Mamoru;
    • Higashio, Takuya;
    • Tsuchida, Shuya;
    • Nishimura, Kazuki;
    • Tsujino, Takuya;
    • Nakamura, Ko;
    • Fukushima, Tatsuo;
    • Nishio, Kyosuke;
    • Yamamoto, Shutaro;
    • Iwatani, Kosuke;
    • Urabe, Fumihiko
    Publication type:
    Article
    9

    Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.

    Published in:
    Targeted Oncology, 2024, v. 19, n. 3, p. 401, doi. 10.1007/s11523-024-01047-y
    By:
    • Uchimoto, Taizo;
    • Tsuchida, Shuya;
    • Komura, Kazumasa;
    • Fukuokaya, Wataru;
    • Adachi, Takahiro;
    • Hirasawa, Yosuke;
    • Hashimoto, Takeshi;
    • Yoshizawa, Atsuhiko;
    • Saruta, Masanobu;
    • Hashimoto, Mamoru;
    • Higashio, Takuya;
    • Matsuda, Takuya;
    • Nishimura, Kazuki;
    • Tsujino, Takuya;
    • Nakamura, Ko;
    • Fukushima, Tatsuo;
    • Nishio, Kyosuke;
    • Yamamoto, Shutaro;
    • Iwatani, Kosuke;
    • Urabe, Fumihiko
    Publication type:
    Article
    10
    11
    12

    Re‐challenging chemotherapy after pembrolizumab in platinum‐refractory urothelial carcinoma.

    Published in:
    BJU International, 2023, v. 131, n. 4, p. 477, doi. 10.1111/bju.15893
    By:
    • Uchimoto, Taizo;
    • Fukushima, Tatsuo;
    • Komura, Kazumasa;
    • Fukuokaya, Wataru;
    • Adachi, Takahiro;
    • Hashimoto, Takeshi;
    • Yoshizawa, Atsuhiko;
    • Nakamura, Ko;
    • Yano, Yusuke;
    • Nishimura, Kazuki;
    • Nishio, Kyosuke;
    • Nakamori, Keita;
    • Iwatani, Kosuke;
    • Yamamoto, Shutaro;
    • Urabe, Fumihiko;
    • Mori, Keiichiro;
    • Yanagisawa, Takafumi;
    • Tsuduki, Shunsuke;
    • Takahara, Kiyoshi;
    • Inamoto, Teruo
    Publication type:
    Article
    13
    14
    15
    16

    Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter study.

    Published in:
    Japanese Journal of Clinical Oncology, 2024, v. 54, n. 11, p. 1208, doi. 10.1093/jjco/hyae098
    By:
    • Urabe, Fumihiko;
    • Imai, Yu;
    • Goto, Yuma;
    • Tashiro, Kojiro;
    • Hashimoto, Masaki;
    • Yoshihara, Kentaro;
    • Yamamoto, Shutaro;
    • Hara, Shuhei;
    • Miyajima, Keiichiro;
    • Fukuokaya, Wataru;
    • Enei, Yuki;
    • Iwatani, Kosuke;
    • Kayano, Sotaro;
    • Igarashi, Taro;
    • Aikawa, Koichi;
    • Yanagisawa, Takafumi;
    • Kimura, Shoji;
    • Tsuzuki, Shunsuke;
    • Murakami, Masaya;
    • Hata, Kenichi
    Publication type:
    Article
    17

    Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab.

    Published in:
    International Journal of Clinical Oncology, 2024, v. 29, n. 5, p. 612, doi. 10.1007/s10147-024-02482-7
    By:
    • Hashimoto, Masaki;
    • Fukuokaya, Wataru;
    • Yanagisawa, Takafumi;
    • Yamamoto, Shutaro;
    • Koike, Yuhei;
    • Imai, Yu;
    • Iwatani, Kosuke;
    • Onuma, Hajime;
    • Ito, Kagenori;
    • Urabe, Fumihiko;
    • Tsuzuki, Shunsuke;
    • Kimura, Shoji;
    • Oyama, Yu;
    • Abe, HIrokazu;
    • Miki, Jun;
    • Kimura, Takahiro
    Publication type:
    Article
    18

    Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab.

    Published in:
    Cancers, 2022, v. 14, n. 22, p. 5659, doi. 10.3390/cancers14225659
    By:
    • Yano, Yusuke;
    • Ohno, Takaya;
    • Komura, Kazumasa;
    • Fukuokaya, Wataru;
    • Uchimoto, Taizo;
    • Adachi, Takahiro;
    • Hirasawa, Yosuke;
    • Hashimoto, Takeshi;
    • Yoshizawa, Atsuhiko;
    • Yamazaki, Shogo;
    • Tokushige, Satoshi;
    • Nishimura, Kazuki;
    • Tsujino, Takuya;
    • Nakamori, Keita;
    • Yamamoto, Shutaro;
    • Iwatani, Kosuke;
    • Urabe, Fumihiko;
    • Mori, Keiichiro;
    • Yanagisawa, Takafumi;
    • Tsuduki, Shunsuke
    Publication type:
    Article
    19
    20
    21
    22

    Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study.

    Published in:
    Clinical Genitourinary Cancer, 2024, v. 22, n. 1, p. 76, doi. 10.1016/j.clgc.2023.09.007
    By:
    • Takuhisa Nukaya;
    • Kiyoshi Takahara;
    • Atsuhiko Yoshizawa;
    • Masanobu Saruta;
    • Yusuke Yano;
    • Takaya Ohno;
    • Taizo Uchimoto;
    • Wataru Fukuokaya;
    • Takahiro Adachi;
    • Shogo Yamazaki;
    • Satoshi Tokushige;
    • Kazuki Nishimura;
    • Takuya Tsujino;
    • Keita Nakamori;
    • Shutaro Yamamoto;
    • Kosuke Iwatani;
    • Fumihiko Urabe;
    • Keiichiro Mori;
    • Takafumi Yanagisawa;
    • Shunsuke Tsuduki
    Publication type:
    Article